Eli Lilly's experimental drug EloraTZP outperformed tirzepatide in a 48-week Phase 2b study, demonstrating superior efficacy in weight reduction and glycemic control. Patients achieved an average weight loss of 23.3%, significantly outpacing the 14.8% reduction seen in the tirzepatide cohort.
Positive Phase 2b data showing EloraTZP delivered greater weight loss and A1C reduction than tirzepatide 15 mg alone is likely to strengthen Lilly's obesity and type 2 diabetes franchise.